Menactra: a meningococcal conjugate vaccine.
Menactra is the first conjugated meningococcal vaccine approved in the US. It protects against meningococcal serogroups A, C, Y and W-135. The CDC's Advisory Committee on Immunization Practices (ACIP) recommends administration of the new vaccine to pre-adolescents aged 11 or 12, teens entering high school and college freshmen living in dormitories. These broad recommendations have led to a shortage of the new vaccine. Menomune, the old unconjugated quadrivalent meningococcal vaccine, is also effective in these age groups and could still be used.